Get access

Preventing Crystallization of Phospholipids in Monolayers: A New Approach to Lung-Surfactant Therapy

Authors

  • Frédéric Gerber,

    1. Institut Charles Sadron (CNRS UPR 22), 6 rue Boussingault, 67083 Strasbourg Cedex, France, Fax: (+33) 388-414-099
    2. Laboratoire de Chimie Bioorganique (UMR 7514), Université Louis Pasteur, 74 Route du Rhin, 67401 Illkirch, France
    Search for more papers by this author
  • Marie Pierre Krafft Dr.,

    1. Institut Charles Sadron (CNRS UPR 22), 6 rue Boussingault, 67083 Strasbourg Cedex, France, Fax: (+33) 388-414-099
    Search for more papers by this author
  • Thierry F. Vandamme Dr.,

    1. Laboratoire de Chimie Bioorganique (UMR 7514), Université Louis Pasteur, 74 Route du Rhin, 67401 Illkirch, France
    Search for more papers by this author
  • Michel Goldmann,

    1. Laboratoire pour l'Utilisation du Rayonnement Electromagnétique (LURE, UMR 130), Centre Universitaire Paris Sud, Bât 209D, 91898 Orsay Cedex, France
    2. Institut des Nano-Sciences de Paris (INSP-UMR CNRS 7588), Campus Boucicaut, 140 rue de Lourmel, 75015 Paris, France
    Search for more papers by this author
  • Philippe Fontaine Dr.

    1. Laboratoire pour l'Utilisation du Rayonnement Electromagnétique (LURE, UMR 130), Centre Universitaire Paris Sud, Bât 209D, 91898 Orsay Cedex, France
    2. Institut des Nano-Sciences de Paris (INSP-UMR CNRS 7588), Campus Boucicaut, 140 rue de Lourmel, 75015 Paris, France
    Search for more papers by this author

  • We thank Alliance Pharmaceutical Corporation (San Diego, CA, USA) for the gift of perfluorooctyl bromide.

Abstract

original image

Control of phospholipid monolayer fluidity: A fluorocarbon gas (gFC) has a highly effective fluidizing effect on a semicrystalline monolayer of dipalmitoylphosphatidylcholine (DPPC, the main component of native lung surfactant), prevents it from crystallizing, and induces the dissolution of pre-existing liquid-condensed-phase domains (see fluorescence micrographs; left: without gFC, right: with gFC). The biocompatible FC may, therefore, prove useful in lung-surfactant therapy.

Ancillary